.png)
TL;DREarly benefit assessment (frühe Nutzenbewertung) evaluates a medicine with a new active substance under §35a SGB V, conducted by the Gemeinsamer Bundesausschuss (G-BA) and usually the IQWiG to determine its additional benefit (Zusatznutzen) over an appropriate comparator therapy.
It is the scientific first half of the AMNOG procedure. The assessment answers one question: does the new medicine help patients more than the therapy already reimbursed by the statutory health insurance? Its outcome then feeds the commercial second half, the negotiated Erstattungsbetrag. Understanding the assessment on its own matters, because the Zusatznutzen category a product receives sets the ceiling for everything that follows in the price negotiation.
§35a SGB V requires the G-BA to assess the benefit of every reimbursable medicine with a new active substance. The trigger is the launch: the manufacturer must submit a structured dossier at the point of first marketing (Inverkehrbringen), and within four weeks for a newly approved indication. The dossier documents the approved indications, the medical benefit, the additional benefit versus the appropriate comparator therapy (zweckmäßige Vergleichstherapie), the number of eligible patients, and the annual therapy cost. If the manufacturer submits no valid dossier, the medicine counts as having no proven additional benefit.
The G-BA is the decision maker. In practice it commissions the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) to carry out the scientific evaluation of the dossier. The IQWiG produces an independent, evidence based assessment; the G-BA can also assess in-house or commission third parties. The distinction matters: the IQWiG advises, the G-BA decides. The final Beschluss is a G-BA resolution, and it becomes an annex to the Arzneimittel-Richtlinie.
The assessment does not produce a yes or no. It grades the additional benefit on a scale defined in §5 of the Arzneimittel-Nutzenbewertungsverordnung (AM-NutzenV). The grade is set per patient group, so one product can hold different categories for different populations. The six categories are:
| Category (German) | English | Meaning |
|---|---|---|
| Erheblicher Zusatznutzen | Major | Sustained, previously unachieved large improvement in therapeutically relevant benefit |
| Beträchtlicher Zusatznutzen | Considerable | Previously unachieved marked improvement |
| Geringer Zusatznutzen | Minor | Previously unachieved moderate, not merely marginal improvement |
| Nicht quantifizierbarer Zusatznutzen | Non-quantifiable | An additional benefit exists but the evidence does not allow it to be graded |
| Kein Zusatznutzen belegt | Not proven | No additional benefit over the comparator was demonstrated |
| Geringerer Nutzen | Lesser benefit | The benefit is lower than that of the appropriate comparator therapy |
The early benefit assessment follows a fixed statutory clock that ends, at the latest, six months after launch.
The Beschluss then hands over to the second AMNOG stage: the negotiation of the Erstattungsbetrag with the GKV-Spitzenverband under §130b SGB V, which starts from the assessed benefit.
These three terms are often blurred, yet they answer different questions. The early benefit assessment asks whether a medicine helps more (§35a SGB V). The Erstattungsbetrag asks what it should then cost, negotiated from that benefit (§130b SGB V). The Festbetrag is a separate reference-price cap for groups of comparable, usually established products (§35 SGB V) and applies to substances that are not, or no longer, in the AMNOG benefit route. The whole two-stage law itself is the AMNOG; this entry covers only its first, scientific stage.
The G-BA Beschluss and the IQWiG assessment reports live at the G-BA and the IQWiG. pharmazie.com does not host those documents. What the platform carries per PZN is the downstream commercial result: the current price and reimbursement status that a completed assessment and its negotiation produce for a specific package.
One honest limitation: pharmazie.com is a data aggregator, not the benefit-assessment authority. It cannot tell you the Zusatznutzen category, the comparator therapy or the reasoning behind a decision. For the assessment itself, the G-BA Beschluss and the IQWiG dossier assessment remain the primary sources.
